Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 18, Pages 4221
Publisher
MDPI AG
Online
2021-09-18
DOI
10.3390/jcm10184221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
- (2020) Takaya Ikeda et al. Thoracic Cancer
- Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
- (2019) Minoru Fukuda et al. LUNG CANCER
- Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer
- (2019) Midori Shimada et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies
- (2019) Jessica A. Hellyer et al. LUNG CANCER
- Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy
- (2018) Mika Saigusa et al. Oncology Research and Treatment
- Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer
- (2017) Shinnosuke Takemoto et al. Thoracic Cancer
- Myeloid Growth Factors
- (2017) Jeffrey Crawford et al. Journal of the National Comprehensive Cancer Network
- A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
- (2016) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
- (2015) Kyoichi Kaira et al. International Journal of Clinical Oncology
- Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
- (2015) Tetsuya Abe et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702
- (2015) Akira Inoue et al. LUNG CANCER
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)
- (2014) Haruyasu Murakami et al. LUNG CANCER
- The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
- (2013) G. H. Lyman et al. ANNALS OF ONCOLOGY
- Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial
- (2012) Chiyoe Kitagawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Amrubicin Monotherapy for Patients with Previously Treated Advanced Large-cell Neuroendocrine Carcinoma of the Lung
- (2011) H. Yoshida et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
- (2010) David S. Ettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
- (2010) Robert Jotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)
- (2010) Hiroyasu Kaneda et al. Journal of Thoracic Oncology
- A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
- (2009) Kyoichi Kaira et al. LUNG CANCER
- Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
- (2008) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More